Effect of treatment with fluosol and mannitol during temporary middle cerebral artery occlusion in cats.
Four groups of seven cats each were subjected to 6 hours of temporary middle cerebral artery (MCA) occlusion followed by reperfusion. During the first 30 minutes of the occlusion, Group 1 received 20% Fluosol-DA (FDA) and Group 2 received 20% FDA and mannitol; Group 3 received 20% FDA and mannitol 30 minutes before the occlusion, and Group 4 (control) received an infusion of saline solution during the first 30 minutes of occlusion. All cats breathed 100% oxygen throughout the occlusion and during 2 hours of reperfusion. Blood pressure, PaO2, and pH remained stable for 8 hours. PaO2 increased from an average base line level of 102 +/- 15 (SD) torr to 520 +/- 45 torr in Group 1, 450 +/- 41 torr in Group 2, 480 +/- 28 torr in Group 3, and 396 +/- 151 torr in Group 4 during the administration of 100% oxygen. The average fluorocrit during occlusion was 6% in Groups 1, 2, and 3. The 24-hour mortality rate was 71% in Group 1, 43% in Group 2, 29% in Group 3, and 14% in Group 4; a midline shift and herniation were present after each fatal infarct. The survivors were sacrificed 10 days after the occlusion. There was a trend toward improvement of neurological function at sacrifice in Groups 2 and 3 compared with Groups 1 and 4. The infarct areas on coronal sections were 2.4 times larger in Group 1 (FDA only) than in Group 4 (control) (P less than 0.05). There was no significant difference in infarct size between Group 4 and Group 2 or 3.(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D001157:Arterial Occlusive Diseases / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D002415:Cats; D002544:Cerebral Infarction / Q000209:etiology / Q000473:pathology; D002561:Cerebrovascular Disorders / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004338:Drug Combinations / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005466:Fluorocarbons / Q000627:therapeutic use*; D006895:Hydroxyethyl Starch Derivatives; D008353:Mannitol / Q000627:therapeutic use*; D009420:Nervous System / Q000503:physiopathology; D015427:Reperfusion Injury / Q000209:etiology / Q000517:prevention & control
D004338:Drug Combinations; D005466:Fluorocarbons; D006895:Hydroxyethyl Starch Derivatives; D008353:Mannitol; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination